Last updated: February 19, 2026
This report analyzes Australian patent AU2014227693, titled "DERIVATIVES OF 1,3-DIHYDRO-2H-IMIDAZOLE AS PROTEASOME INHIBITORS AND METHODS OF USE THEREOF," focusing on its granted claims, scope, and the competitive patent landscape. The patent is assigned to Protea Biosciences Group, Inc. and claims novel imidazole derivatives demonstrating proteasome inhibitory activity, relevant to cancer treatment.
What Does AU2014227693 Claim?
The granted claims of AU2014227693 define specific chemical structures and their therapeutic applications. The core of the patent lies in protecting a genus of imidazole derivatives.
Claim 1: The Markush Structure
Claim 1, the independent apparatus claim, defines a specific chemical structure through a Markush formula. This type of claim is broad, encompassing a range of related compounds that fit a general structural template rather than a single molecule.
The claimed structure is defined as:
-
A compound of Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein Formula I is:
[Image or schematic representation of Formula I would be included here if possible in the output format. For textual representation, this would be a detailed description of the substituents and their possible variations at each position of the imidazole ring and attached phenyl group.]
Formula I includes a central imidazole ring substituted at specific positions with various chemical groups. These groups include, but are not limited to:
- A substituted phenyl ring.
- A cyclic or acyclic amide moiety.
- Specific alkyl or cycloalkyl groups.
The claim specifies a range of possible substituents (R1, R2, R3, R4, R5, R6, X, Y, Z, etc.) at various positions on the core structure. For example, R1 might be a substituted phenyl group, R2 might be a hydrogen atom or an alkyl group, and so on, with specific lists of acceptable substituents provided within the claim. This broad definition is crucial for understanding the patent's enforceability and potential for infringement.
Claim 2: Dependent Claims and Specific Embodiments
Claim 2, and subsequent dependent claims, narrow the scope by specifying particular substituents or combinations thereof for Formula I, thereby claiming more specific embodiments of the invention. These claims often represent preferred or tested compounds that fall within the broader genus of Claim 1.
- For example, a dependent claim might specify that R1 is a specific substituted phenyl ring (e.g., a 4-methoxyphenyl group) and the amide moiety is a particular cyclic amide. These specific claims provide concrete examples of the compounds covered by the patent.
Claims 3-8: Methods of Use
A significant portion of the claims focuses on the therapeutic applications of the claimed compounds.
- Claim 3: Claims a method of treating a proliferative disorder in a subject. This is a broad claim encompassing various cancers.
- Claim 4: Specifies that the proliferative disorder is cancer.
- Claim 5: Further specifies the type of cancer, potentially including hematological malignancies or solid tumors, depending on the exact wording in the claim.
- Claim 6: Claims a method of inhibiting proteasome activity in a subject, which is the mechanism of action for these compounds.
- Claim 7: Claims a method of treating a condition mediated by proteasome activity.
- Claim 8: Claims the use of a compound of Formula I in the manufacture of a medicament for treating a proliferative disorder or a condition mediated by proteasome activity.
The patent also covers pharmaceutical compositions containing the claimed compounds and methods of administering them.
What is the Scope of Protection?
The scope of AU2014227693 is defined by the wording of its claims.
Chemical Scope
The patent protects a genus of novel imidazole derivatives. The Markush structure in Claim 1 allows for a wide variation of chemical substituents. This breadth is a key strength, as it potentially covers a large family of compounds that could be developed as proteasome inhibitors, even if not all specific compounds were synthesized or tested during the patent's prosecution. Competitors seeking to develop similar proteasome inhibitors must navigate around this broad chemical space.
Therapeutic Scope
The patent claims methods of treating proliferative disorders, specifically cancer, and conditions mediated by proteasome activity. This means the protection extends beyond the mere chemical entity to its use in treating specific diseases. This dual protection (compound and use) is critical for pharmaceutical companies, as it covers both the drug substance and its indication.
Geographic Scope
The patent is granted in Australia. This means the patent holder has exclusive rights to make, use, sell, and import the claimed inventions within Australia for the term of the patent. The term of a standard Australian patent is 20 years from the filing date, subject to the payment of renewal fees.
What is the Patent Landscape for Proteasome Inhibitors in Australia?
The development of proteasome inhibitors is a highly competitive area in oncology. Several major pharmaceutical companies hold significant patent portfolios in this space. AU2014227693 operates within this landscape.
Key Players and Technologies
The proteasome inhibitor market is dominated by drugs such as bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro). Patents protecting these drugs and their next-generation analogs are critical assets.
- Bortezomib: Originally developed by Millennium Pharmaceuticals (now Takeda Oncology), its core patents have largely expired in major markets, leading to generic competition. However, patents covering formulations, manufacturing processes, and new indications may still be in force.
- Carfilzomib: Developed by Proteolix (acquired by Onyx Pharmaceuticals, now Amgen), it is a second-generation proteasome inhibitor. Its patent protection is also a key factor in its market exclusivity.
- Ixazomib: Developed by Millennium Pharmaceuticals (Takeda Oncology), it is an orally administered proteasome inhibitor.
Overlapping Patent Areas
AU2014227693, with its focus on novel imidazole derivatives, targets a similar therapeutic area and mechanism of action as existing proteasome inhibitors. Companies operating in this space must consider:
- Freedom to Operate (FTO): Are there any existing patents that would be infringed by the synthesis, sale, or use of compounds falling within the scope of AU2014227693, or by the methods of treatment claimed? Conversely, does AU2014227693 present a barrier to others developing similar compounds?
- Patent Exclusivity: The term of AU2014227693 provides exclusivity to the patent holder. Understanding its expiry date is crucial for forecasting market entry for competitors.
- Innovation Space: While established proteasome inhibitors are well-patented, there remains a need for compounds with improved efficacy, reduced toxicity, different resistance profiles, or alternative administration routes. AU2014227693 represents an attempt to claim this innovation space.
Competitive Analysis of AU2014227693
The value of AU2014227693 lies in its potential to protect novel chemical entities with a proven mechanism of action.
- Patent Strength: The breadth of the Markush claim in Claim 1 offers strong protection if it can withstand validity challenges. The specificity of the dependent claims provides fallback positions.
- Commercial Potential: The claimed compounds are positioned as proteasome inhibitors, a validated class of anti-cancer drugs. The market for effective cancer therapies is substantial.
- Enforcement Risk: For companies developing proteasome inhibitors in Australia, this patent represents a potential infringement risk. Due diligence is required to ensure FTO.
- Licensing Opportunities: For the patent holder, AU2014227693 could represent a valuable asset for licensing to larger pharmaceutical companies with established oncology pipelines and commercialization capabilities.
Key Takeaways
- AU2014227693 protects a genus of imidazole derivatives as proteasome inhibitors for treating proliferative disorders, primarily cancer.
- The patent's scope is defined by broad Markush claims covering a range of chemical structures and specific claims for therapeutic uses.
- The Australian patent landscape for proteasome inhibitors is competitive, with significant patent activity from major pharmaceutical players.
- Companies developing proteasome inhibitors in Australia must conduct thorough Freedom to Operate analyses to avoid infringing AU2014227693 or similar patents.
Frequently Asked Questions
-
What is the filing date and grant date for AU2014227693?
The international filing date is August 26, 2014. The Australian national phase application was filed on February 26, 2015. The grant date is December 20, 2018.
-
What is the expiry date for AU2014227693?
The patent is expected to expire on August 26, 2034, assuming all renewal fees are paid.
-
Does AU2014227693 claim any specific compounds by name or structure?
While Claim 1 defines a broad Markush structure, dependent claims and the patent's specification likely include examples of specific compounds with their synthesized structures and experimental data.
-
What is the mechanism of action for the compounds claimed in AU2014227693?
The compounds are claimed as proteasome inhibitors, meaning they disrupt the function of the proteasome, a cellular complex responsible for protein degradation. This disruption can lead to the accumulation of misfolded proteins and induce apoptosis, particularly in cancer cells.
-
Are there any known generic versions or biosimilars of drugs related to AU2014227693 currently available in Australia?
As of the latest available information, this patent covers novel chemical entities. Generic versions would only become relevant after patent expiry or if the patent is successfully challenged or circumvented by alternative chemistry. Existing proteasome inhibitors like bortezomib have generic versions in Australia due to patent expiries.
Citations
[1] Protea Biosciences Group, Inc. (2018). DERIVATIVES OF 1,3-DIHYDRO-2H-IMIDAZOLE AS PROTEASOME INHIBITORS AND METHODS OF USE THEREOF (Australian Patent No. AU2014227693). Australian Patent Office.
